Brief: Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
09/02/2026 02:05
Feb 8 (Reuters) - Biogen BIIB.O: BIOGEN: BIOLOGICS LICENSE APPLICATION FOR SUBCUTANEOUS FORMULATION OF LEQEMBI FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE DESIGNATED FOR PRIORITY REVIEW IN CHINA Source text: https://tinyurl.com/ye2b3au3 Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China